These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38261266)

  • 21. Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review.
    Liu Y; Li J; Zhu HJ
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):377-397. PubMed ID: 38706437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of regulatory variants of carboxylesterase 1 (CES1): A proof-of-concept study for the application of the Allele-Specific Protein Expression (ASPE) assay in identifying cis-acting regulatory genetic polymorphisms.
    Her L; Shi J; Wang X; He B; Smith LS; Jiang H; Zhu HJ
    Proteomics; 2023 Jan; 23(1):e2200176. PubMed ID: 36413357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of CES1 genotypes on the pharmacokinetics of methylphenidate in healthy Danish subjects.
    Stage C; Jürgens G; Guski LS; Thomsen R; Bjerre D; Ferrero-Miliani L; Lyauk YK; Rasmussen HB; Dalhoff K;
    Br J Clin Pharmacol; 2017 Jul; 83(7):1506-1514. PubMed ID: 28087982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review.
    Kubo SH; Cody RJ
    Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Major implications of single nucleotide polymorphisms in human carboxylesterase 1 on substrate bioavailability.
    Yerrakula G; Abraham S; John S; Zeharvi M; George SG; Senthil V; Maiz F; Rahman MH
    Biotechnol Genet Eng Rev; 2022 Aug; ():1-19. PubMed ID: 35946821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response.
    Lewis JP; Horenstein RB; Ryan K; O'Connell JR; Gibson Q; Mitchell BD; Tanner K; Chai S; Bliden KP; Tantry US; Peer CJ; Figg WD; Spencer SD; Pacanowski MA; Gurbel PA; Shuldiner AR
    Pharmacogenet Genomics; 2013 Jan; 23(1):1-8. PubMed ID: 23111421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects.
    Neuvonen M; Tarkiainen EK; Tornio A; Hirvensalo P; Tapaninen T; Paile-Hyvärinen M; Itkonen MK; Holmberg MT; Kärjä V; Männistö VT; Neuvonen PJ; Pihlajamäki J; Backman JT; Niemi M
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):341-345. PubMed ID: 28990360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis.
    Lian J; Bahitham W; Panigrahi R; Nelson R; Li L; Watts R; Thiesen A; Lemieux MJ; Lehner R
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Jul; 1863(7):688-699. PubMed ID: 29631096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory effects of genomic translocations at the human carboxylesterase-1 (CES1) gene locus.
    Sanford JC; Wang X; Shi J; Barrie ES; Wang D; Zhu HJ; Sadee W
    Pharmacogenet Genomics; 2016 May; 26(5):197-207. PubMed ID: 26871237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormetic effects of EGC and EGCG on CES1 activity and its rescue from oxidative stress in rat liver S9.
    Luo X; Lu F; Yin Z; Zhou Z; Wang Z; Zhang H
    Chem Biol Interact; 2023 Sep; 382():110612. PubMed ID: 37353134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
    Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
    Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologically-Based Pharmacokinetic Modeling to Predict Methylphenidate Exposure Affected by Interplay Among Carboxylesterase 1 Pharmacogenetics, Drug-Drug Interactions, and Sex.
    Xiao J; Shi J; Thompson BR; Smith DE; Zhang T; Zhu HJ
    J Pharm Sci; 2022 Sep; 111(9):2606-2613. PubMed ID: 35526575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition.
    Hu ZY; Edginton AN; Laizure SC; Parker RB
    Clin Pharmacokinet; 2014 Sep; 53(9):825-36. PubMed ID: 25103325
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin.
    Qian Y; Gilliland TK; Markowitz JS
    Chem Biol Interact; 2020 Jan; 316():108914. PubMed ID: 31837295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations.
    Rasmussen HB; Madsen MB; Lyauk YK; Hansen PR; Hughes T;
    Drug Metab Pers Ther; 2017 Sep; 32(3):163-168. PubMed ID: 28803225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
    Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
    Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.
    Zhu HJ; Patrick KS; Yuan HJ; Wang JS; Donovan JL; DeVane CL; Malcolm R; Johnson JA; Youngblood GL; Sweet DH; Langaee TY; Markowitz JS
    Am J Hum Genet; 2008 Jun; 82(6):1241-8. PubMed ID: 18485328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients.
    Matsumoto N; Kubota Y; Ishida H; Sekido M; Ohkuma R; Ishiguro T; Hirasawa Y; Ariizumi H; Tsunoda T; Ikusue T; Kobayashi K; Hisamatsu A; Toshima H; Shimada K; Fujita KI
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1119-1128. PubMed ID: 32458030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.
    Luo JQ; He FZ; Wang ZM; Sun NL; Wang LY; Tang GF; Liu MZ; Li Q; Chen XP; Liu ZQ; Zhou HH; Zhang W
    Sci Rep; 2015 Nov; 5():17253. PubMed ID: 26607661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.